CCX662

Overview

CCX662 is a selective CXCR7 inhibitor with human IC 50 values of 9 nM (buffer) and 18 nM (100% human serum), and rat IC 50 of 14 nM (100% rat serum). CCX662 blocks CXCL12 binding to CXCR7 , inhibits CXCR4 -directed trans-endothelial migration of CXCR4 + / CXCR7 + cells. CCX662 can be used for the research of glioblastoma multiforme.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > CNS Neoplasm | Products > Disease Areas > Glioma | Products > Disease Areas > Glioblastoma Multiforme | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CXCR

Product Information

• Catalog No.: HY-167851
• CAS No.: 1226686-54-9
• Molecular Formula: C28H37N5O4S
• Molecular Weight: 539.69
• Purity: 99.98%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (4.63 mM); Clear solution
• Availability: In-stock

Source

Original product source